aTYR PHARMA INC Accretion Expense
aTYR PHARMA INC (ATYR) reported Accretion Expense of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2023-03-14
- aTYR PHARMA INC accretion expense for the quarter ending 2020-12-31 was $22.00K, a 85.43% decline year-over-year.
- aTYR PHARMA INC accretion expense for the quarter ending 2020-09-30 was $85.00K, a 49.70% decline year-over-year.
- aTYR PHARMA INC accretion expense for the quarter ending 2020-06-30 was $110.00K, a 40.86% decline year-over-year.
- aTYR PHARMA INC accretion expense for the quarter ending 2020-03-31 was $129.00K, a 35.82% decline year-over-year.
- aTYR PHARMA INC accretion expense for fiscal 2022 was $0.00.
- aTYR PHARMA INC accretion expense for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- aTYR PHARMA INC accretion expense for fiscal 2020 was $346.00K, a 51.06% decline from fiscal 2019.
- aTYR PHARMA INC accretion expense for fiscal 2019 was $707.00K, a 26.81% decline from fiscal 2018.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 6 month as first filed | Accretion Expense 9 month | Accretion Expense 9 month as first filed | Accretion Expense 12 month | Accretion Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-14 | ||||||
| 2021-12-31 | $0.00 10-K · filed 2023-03-14 | ||||||
| 2020-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $107.00K derived: sum of 2 quarters · filed 2023-03-14 | $217.00K derived: sum of 3 quarters · filed 2023-03-14 | $346.00K 10-K · filed 2023-03-14 | |||
| 2020-09-30 | $85.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $195.00K derived: sum of 2 quarters · filed 2021-11-12 | $324.00K 10-Q · filed 2021-11-12 | $475.00K derived: sum of 4 quarters · filed 2022-03-15 | |||
| 2020-06-30 | $110.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $239.00K 10-Q · filed 2021-08-11 | $390.00K derived: sum of 3 quarters · filed 2022-03-15 | $559.00K derived: sum of 4 quarters · filed 2022-03-15 | |||
| 2020-03-31 | $129.00K 10-Q · filed 2021-05-14 | $280.00K derived: sum of 2 quarters · filed 2022-03-15 | $449.00K derived: sum of 3 quarters · filed 2022-03-15 | $635.00K derived: sum of 4 quarters · filed 2022-03-15 | |||
| 2019-12-31 | $151.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $320.00K derived: sum of 2 quarters · filed 2022-03-15 | $506.00K derived: sum of 3 quarters · filed 2022-03-15 | $707.00K 10-K · filed 2022-03-15 | |||
| 2019-09-30 | $169.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $355.00K derived: sum of 2 quarters · filed 2020-11-13 | $556.00K 10-Q · filed 2020-11-13 | $779.00K derived: sum of 4 quarters · filed 2021-03-24 | |||
| 2019-06-30 | $186.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $387.00K 10-Q · filed 2020-08-13 | $610.00K derived: sum of 3 quarters · filed 2021-03-24 | $852.00K derived: sum of 4 quarters · filed 2021-03-24 | |||
| 2019-03-31 | $201.00K 10-Q · filed 2020-05-12 | $424.00K derived: sum of 2 quarters · filed 2021-03-24 | $666.00K derived: sum of 3 quarters · filed 2021-03-24 | $1.09M derived: sum of 4 quarters · filed 2021-03-24 | |||
| 2018-12-31 | $223.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $465.00K derived: sum of 2 quarters · filed 2021-03-24 | $885.00K derived: sum of 3 quarters · filed 2021-03-24 | $966.00K 10-K · filed 2021-03-24 | |||
| 2018-09-30 | $242.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $662.00K derived: sum of 2 quarters · filed 2019-11-14 | $743.00K 10-Q · filed 2019-11-14 | $919.00K derived: sum of 4 quarters · filed 2020-03-26 | |||
| 2018-06-30 | $420.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $501.00K 10-Q · filed 2019-08-14 | $677.00K derived: sum of 3 quarters · filed 2020-03-26 | $845.00K derived: sum of 4 quarters · filed 2020-03-26 | |||
| 2018-03-31 | $81.00K 10-Q · filed 2019-05-14 | $257.00K derived: sum of 2 quarters · filed 2020-03-26 | $425.00K derived: sum of 3 quarters · filed 2020-03-26 | $634.00K derived: sum of 4 quarters · filed 2020-03-26 | |||
| 2017-12-31 | $176.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $344.00K derived: sum of 2 quarters · filed 2020-03-26 | $553.00K derived: sum of 3 quarters · filed 2020-03-26 | $590.00K 10-K · filed 2020-03-26 | $192.00K 10-K · filed 2018-03-20 | ||
| 2017-09-30 | $168.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $377.00K derived: sum of 2 quarters · filed 2018-11-14 | $414.00K 10-Q · filed 2018-11-14 | $133.00K 10-Q · filed 2017-11-14 | $457.00K derived: sum of 4 quarters · filed 2019-03-26 | ||
| 2017-06-30 | $209.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $246.00K 10-Q · filed 2018-08-14 | $76.00K 10-Q · filed 2017-08-14 | $289.00K derived: sum of 3 quarters · filed 2019-03-26 | $322.00K derived: sum of 4 quarters · filed 2019-03-26 | ||
| 2017-03-31 | $37.00K 10-Q · filed 2018-05-15 | $80.00K derived: sum of 2 quarters · filed 2019-03-26 | $113.00K derived: sum of 3 quarters · filed 2019-03-26 | ||||
| 2016-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $76.00K derived: sum of 2 quarters · filed 2019-03-26 | $173.00K 10-K · filed 2019-03-26 | ||||
| 2016-09-30 | $33.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | $130.00K 10-Q · filed 2017-11-14 | |||||
| 2016-06-30 | $97.00K 10-Q · filed 2017-08-14 | ||||||
| 2015-12-31 | $297.00K 10-K · filed 2018-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |